SI-BONE SIBN 深 滬
已收盤 12-24 16:00:00 美东时间
20.36
-0.030
-0.15%
華盛通- 最 高20.74
- 今 開20.49
- 成交量 12.31万股
- 最 低 20.02
- 昨 收 20.39
- 總市值 8.83亿
- 52周最高 21.07
- 市盈率 靜 --
- 換手率 0.28%
- 52周最低 12.495
- 委 比 -93.87%
- 總股本 4339.13万
- 歷史最高 37.21
- 量 比 0.24
- 振 幅 3.53%
- 歷史最低 7.20
- 每 手 1
- 風險率 1.88%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅101%！12家机构集体上调美光目标价；Insmed、RPM、Vital Farms等遭多家大行下调评级
今日重点评级关注：Ascendiant Capital：维持Society Pass"买入"评级，目标价从22美元升至22.5美元；HC Wainwright & Co.：维持Climb Bio"买入"评级，目标价从9美元升至11美元
12-19 10:15
美股大行评级 | 德银首予Coinbase"买入"评级，目标价340美元；AERO获多家机构首予超配评级；大摩维持苹果"超配"评级，目标价升至315美元
今日重点评级关注：巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从9美元升至10美元；摩根大通：上调Recursion Pharmaceuticals评级至"超配"，目标价从10美元升至11美元
12-18 10:54
美股大行评级 | 潜在涨幅263.64%！Milestone Pharmaceuticals获富国银行升目标价至8美元，维持"超配"评级
今日重点评级关注：富国银行：维持Milestone Pharmaceuticals"超配"评级，目标价从4美元升至8美元；富国银行：维持Kyverna Therapeutics"超配"评级，目标价从31美元升至33美元
12-17 10:46
Needham Maintains Buy on SI-BONE, Raises Price Target to $27
Needham analyst David Saxon maintains SI-BONE (NASDAQ:SIBN) with a Buy and raises the price target from $24 to $27.
12-16 20:11
美股大行评级 | 最高500美元！MongoDB获18家大行紧急上调目标价；巴克莱下调理想汽车目标价至18美元
今日重点评级关注：B. Riley证券：维持Seabridge Gold"买入"评级，目标价从50美元升至65美元；HC Wainwright & Co.：维持TRX Gold"买入"评级，目标价从1.2美元升至1.4美元
12-03 09:58
Morgan Stanley Maintains Overweight on SI-BONE, Raises Price Target to $23
Morgan Stanley analyst Drew Ranieri maintains SI-BONE (NASDAQ:SIBN) with a Overweight and raises the price target from $20 to $23.
12-03 01:54
SI-BONE To Present at Piper Sandler 37th Annual Healthcare Conference on December 2, 2025
SI-BONE, a medical device company specializing in sacropelvic disorder treatments, announced its participation in the Piper Sandler 37th Annual Healthcare Conference in New York. The company's management will host a fireside chat on December 2, 2025, at 9:00 a.m. PST/12:00 p.m. EST. Interested investors can access the live audio via the company's website or through the provided registration link. The webcast will be archived for at least 90 days....
11-18 21:09
SI-BONE shares are trading higher after the company reported Q3 earnings and revenue above estimates and raised its FY2025 sales guidance.
SI-BONE shares are trading higher after the company reported Q3 earnings and re...
11-11 22:44
SI-BONE Raises FY2025 Sales Guidance from $195.000M-$198.000M to $198.000M-$200.000M vs $196.584M Est
SI-BONE (NASDAQ:SIBN) raises FY2025 sales outlook from $195.000 million-$198.000 million to $198.000 million-$200.000 million vs $196.584 million estimate.
11-11 05:10
SI-BONE Q3 EPS $(0.11) Beats $(0.17) Estimate, Sales $48.656M Beat $46.667M Estimate
SI-BONE (NASDAQ:SIBN) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.17) by 36.05 percent. This is a 31.25 percent increase over losses of $(0.16) per share from the same
11-11 05:09
